Fairvalue-Calculator Fairvalue-Calculator
EN DE

Wanbangde Pharmaceutical Holding (002082) Fair Value & Analysis

Healthcare · CN · Market cap 8.0B CNY

Price¥12.97
Fair Value¥12.34
Upside-4.9%
Quality92/100
Evidence: Medium Range ¥9.25 – ¥15.42

Fair value as of: Jun 25, 2026

Analysis

Wanbangde Pharmaceutical Holding (002082) currently trades at ¥12.97, while our model-based Fair Value estimate is ¥12.34 — implying the stock looks roughly 4.9% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Wanbangde Pharmaceutical Holding Group Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicine, chemical raw materials, and chemical preparations in China and internationally. The company operates through two segments, the Pharmaceutical Business and the Medical Device Business. It offers drugs products used to treat cardiovascular and cerebrovascular diseases; and nervous, respiratory, mental, and digestive system diseases. The company also develops and sells orthopedic implant devices, including orthopedic implant devices comprised of thoracolumbar fusion, cervical fusion, spinal internal fixation systems, independent fusion devices, unicompartmental knee joints, etc.; medical equipment; disposable sterile medical polymer consumables; and hospital engineering services. The company was formerly known as Wanbangde New Building Materials Co., Ltd. and changed its name to Wanbangde Pharmaceutical Holding Group Co., Ltd. in April 2020. Wa…

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +885% Jiangsu Hengrui Pharmaceuticals Co (600276) -44% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -75% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -78%

Frequently asked questions

Is Wanbangde Pharmaceutical Holding (002082) undervalued?
As of Jun 25, 2026, our model estimates a fair value of ¥12.34 versus a price of ¥12.97 — about −5% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 002082?
Our 21-model fair value for Wanbangde Pharmaceutical Holding is ¥12.34 (as of Jun 25, 2026), built from audited fundamentals. The current price is ¥12.97.
What is the quality score of 002082?
Wanbangde Pharmaceutical Holding has a Quality Score of 92/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.